Non-GAAP Operating Expenses: $175.3 million for the full year 2024, down from $596.5 million in the previous year. Summit Therapeutics Inc (NASDAQ:SMMT) announced a clinical trial collaboration ...

In a report released today, Bradley Canino from Stifel Nicolaus maintained a Buy rating on Summit Therapeutics (SMMT – Research Report), with a ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other ... However, the full year remained strong, with net losses narrowing by 64 ...

Deep-pocketed investors have adopted a bullish approach towards Summit Therapeutics (NASDAQ:SMMT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against the other hot growth stocks. The big rally in the broader stock market might have ceased, ...

SUMMIT THERAPEUTICS ($SMMT) posted quarterly earnings results on Monday, February 24th. The company reported earnings of -$0.08 per share, beating estimates of -$0.08 ...

Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report ... The consensus estimate for Summit Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates ...